Only logged in customers who have purchased this product may leave a review.
|Settings||vitamin C,D3 & Zinc remove||Mosedin® Syrup- 60ml remove||CEFAMOR dry syrup remove||Bronchophane Syrup remove||Ambrodil Drops remove||Ambrox Syrup remove|
|Name||vitamin C,D3 & Zinc remove||Mosedin® Syrup- 60ml remove||CEFAMOR dry syrup remove||Bronchophane Syrup remove||Ambrodil Drops remove||Ambrox Syrup remove|
|Add to cart|
|Description||Vitamin C,vitamin D3 and Zinc all in one|
Tablets: Each tablet contains : Loratadine 10 mg Inactive ingredients: Calcium phosphate dihydrate, lactose monohydrate, a vicel PH 102, povidone XL (crospovidone), povidone k 30, magnesium stearate, talc purified, aerosil 200 Syrup|: Each teaspoonful ( 5 ml ) contains : Loratadine 5 mg Inactive ingredients: Propylene glycol, tween 80, sucrose, citric acid monohydrate, benzoic acide, saccharine sodium, veltol plus, strawberry flavour, alcohol, purified water
Indications And Usage:
Mosedin® is indicated for the relief of nasal and non-nasal symptoms of seasonal allergic rhinitis and for the treatment of chronic idiopathic urticaria in patients 2 years of age or older.
Mosedin® is contraindicated in patients who are hypersensitive to this medication or to any of its ingredients. PRECAUTIONS: General: Patients with liver impairment or renal insufficiency (GFR < 30 mL/min) should be given a lower initial dose (10 mg every other day).
Mosedin® Tablets: Reported adverse events with an incidence of more than 2% in allergic rhinitis patients & chronic idiopathic urticaria. 12 years of age and older are: headache, somnolence ,fatigue , dry mouth Mosedin® Syrup: Adverse events in these pediatric patients were observed to occur with type and frequency similar to those seen in the adult population. The rate of premature discontinuance due to adverse events among pediatric patients receiving loratadine 10 mg daily was less than 1%. Adverse events occurring with a frequency of ≥>_ 2% in loratadine syrup-treated patients (6 to 12 years old) are: Nervousness, wheezing, fatigue, hyperkinesia , abdominal pain, conjunctivitis, dysphonia, malaise, upper respiratory tract infection In pediatric patients 2 to 5 years of age received 5 mg loratadine once daily for a period of 14 days. No unexpected adverse events were seen given the known safety profile of loratadine and likely adverse reactions for this patient population. The following adverse events occurred with a frequency of 2 to 3 percent in the loratadine syrup-treated patients (2 to 5 years old) : diarrhea, epistaxis, pharyngitis, influenza-like symptoms, fatigue, stomatitis, tooth disorder, earache, viral infection, and rash. In addition to those adverse events reported above (≥>_ 2%), the following adverse events have been reported in at least one patient in loratidine clinical trials in adult and pediatric patients: Autonomic Nervous System: altered lacrimation, altered salivation, flushing, hypoesthesia, impotence, increased sweating, thirst. Body as a Whole: angioneurotic edema, asthenia, back pain, blurred vision, chest pain, earache, eye pain, fever, leg cramps, malaise, rigors, tinnitus, weight gain. Cardiovascular System: hypertension, hypotension, palpitations, supraventricular tachyarrhythmias, syncope, tachycardia. Central and Peripheral Nervous System: blepharospasm, dizziness, dysphonia, hypertonia, migraine, paresthesia, tremor, vertigo. Gastrointestinal System: altered taste, anorexia, constipation, diarrhea, dyspepsia, flatulence, gastritis, hiccup, increased appetite, loose stools, nausea, vomiting. Musculoskeletal System: arthralgia, myalgia. Psychiatric: agitation, amnesia, anxiety, confusion, decreased libido, depression, impaired concentration, insomnia, irritability, paroniria. Reproductive System: breast pain, dysmenorrhea, menorrhagia, vaginitis. Respiratory System: bronchitis, bronchospasm, coughing, dyspnea, hemoptysis, laryngitis, nasal dryness, sinusitis, sneezing. Skin and Appendages: dermatitis, dry hair, dry skin, photosensitivity reaction, pruritus, purpura, urticaria. Urinary System: altered micturition, urinary discoloration, urinary incontinence, urinary retention. In addition, the following spontaneous adverse events have been reported rarely during the marketing of loratadine: abnormal hepatic function, including jaundice, hepatitis, and hepatic necrosis; alopecia; anaphylaxis; breast enlargement; erythema multiforme; peripheral edema; thrombocytopenia; and seizures.
Dosage & Administration:
Adults and children 6 years of age and over: The recommended dose of Mosedin® is one 10 mg tablet , or 2 teaspoonfuls (10 mg) of syrup once daily. Children 2 to 5 years of age: The recommended dose of Mosedin® Syrup is 5 mg (1 teaspoonful) once daily. In adults and children 6 years of age and over with liver failure or renal insufficiency (GFR < 30 mL/min), the starting dose should be 10 mg (one tablet or two teaspoonfuls) every other day. In children 2 to 5 years of age with liver failure or renal insufficiency, The starting dose should be 5 mg (one teaspoonful) every other day. Never to be used for children less than 2 years In case of children less than 6 years, it should be prescribed by the physician
Loratadine (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, cimetidine, and ketoconazole in controlled clinical pharmacology studies in adult volunteers. Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers, there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events. There were no significant effects on QTc intervals, and no reports of sedation or syncope. No effects on plasma concentrations of cimetidine or ketoconazole were observed. Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone. The clinical relevance of this difference is unknown. There does not appear to be an increase in adverse events in subjects who received oral contraceptives and loratadine. Pregnancy Category B: Mosedin® should be used during pregnancy only if clearly needed. Nursing Mothers: Loratadine and its metabolite, descarboethoxyloratadine, pass easily into breast milk and achieve concentrations that are equivalent to plasma levels with an AUCmilk/AUCplasma ratio of 1.17 and 0.85 for loratadine and descarboethoxyloratadine, respectively. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Caution should be exercised when Mosedin® is administered to a nursing woman. Pediatric Use: The safety of Mosedin® Syrup at a daily dose of 10 mg has been demonstrated in pediatric patients 6 to 12 years of age. The safety and tolerability of Mosedine® Syrup at a daily dose of 5 mg has been demonstrated in pediatric patients 2 to 5 years of age . The effectiveness of Mosedin® for the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria in children aged 2 to 12 years is based on an extrapolation of the demonstrated efficacy of Mosedin® in adults in these conditions and the likelihood that the disease course, pathophysiology, and the drug’s effect are substantially similar to that of the adults. The recommended dose for the pediatric population is based on cross-study comparison of the pharmacokinetics of Mosedin® in adults and pediatric subjects and on the safety profile of loratadine in both adults and pediatric patients at doses equal to or higher than the recommended doses. The safety and effectiveness of Mosedin® in children under 2 years of age have not been established.
Tablets: Carton box containing 1, 2, 3 strips each of 10 tablets. Syrup: Bottles of 60 ml with graduated spoon.
Clinical Pharmacology In Adults:
Loratadine is a long-acting tricyclic antihistamine with selective peripheral histamine H1-receptor antagonistic activity. Mosedin® exhibits an antihistaminic effect beginning within 1 to 3 hours, reaching a maximum at 8 to 12 hours, and lasting in excess of 24 hours. There was no evidence of tolerance to this effect after 28 days of dosing with Mosedin®. Neither loratadine nor its metabolites readily cross the bloodbrain barrier. Mosedin® has preferential binding to peripheral versus central nervous system H1-receptors.
Absorption: Loratadine was rapidly absorbed following oral administration with maximum concentration (Tmax) of 1.3 hours for loratadine and 2.5 hours for its major active metabolite, descarboethoxyloratadine. The pharmacokinetics of loratadine and descarboethoxyloratadine are independent of dose over the dose range of 10 mg to 40 mg and are not altered by the duration of treatment. Peak plasma concentrations (Cmax) were not affected by food. Metabolism: loratadine is metabolized to descarboethoxyloratadine predominantly by cytochrome P450 3A4 (CYP3A4) and, to a lesser extent, by cytochrome P450 2D6 (CYP2D6). In the presence of a CYP3A4 inhibitor ketoconazole, loratadine is metabolized to descarboethoxyloratadine predominantly by CYP2D6. Concurrent administration of loratadine with either ketoconazole, erythromycin (both CYP3A4 inhibitors), or cimetidine (CYP2D6 and CYP3A4 inhibitor) to healthy volunteers was associated with substantially increased plasma concentrations of loratadine . Elimination: Approximately 80% of the total loratadine dose administered can be found equally distributed between urine and feces in the form of metabolic products within 10 days. In nearly all patients, exposure (AUC) to the metabolite is greater than to the parent loratadine. The mean elimination half-lives in normal adult subjects were 8.4 hours (range = 3 to 20 hours) for loratadine and 28 hours (range = 8.8 to 92 hours) for descarboethoxyloratadine. Loratadine and descarboethoxyloratadine reached steady-state in most patients by approximately the fifth dosing day. Special Populations: Pediatric: The pharmacokinetic profile of loratadine in children in the 6- to 12-year age group is similar to that of adults. The pharmacokinetic profile of loratadine in children in the 2 to 5-year age group is similar to that of adults. Geriatric: In healthy geriatric subjects (66 to 78 years old), the AUC and peak plasma levels (Cmax) of both loratadine and descarboethoxyloratadine were approximately 50% greater than those observed in studies of younger subjects. The mean elimination half-lives for the geriatric subjects were 18.2 hours (range = 6.7 to 37 hours) for loratadine and 17.5 hours (range = 11 to 38 hours) for descarboethoxyloratadine. Renal Impairment: In subjects with chronic renal impairment (creatinine clearance _ 80 mL/min). The mean elimination half-lives of loratadine (7:6 hours) and descarboethoxyloratadine (23.9 hours) were not substantially different from that observed in normal subjects. Hemodialysis does not have an effect on the pharmacokinetics of loratadine or descarboethoxyloratadine in subjects with chronic renal impairment. Hepatic Impairment: In patients with chronic alcoholic liver disease, the AUC and Cmax of loratadine were double while the pharmacokinetic profile of descarboethoxyloratadine was not substantially different from that observed in other trials enrolling normal subjects. The elimination half-lives for loratadine and descarboethoxyloratadine were 24 hours and 37 hours, respectively, and increased with increasing severity of liver disease.
Store at temperature not exceeding 30 ˚
In adults, somnolence, tachycardia, and headache have been reported with overdoses greater than 10 mg with the Tablet formulation (40 mg -180 mg). Extrapyramidal signs and palpitations have been reported in children with overdoses of greater than 10 mg of loratidine Syrup. In the event of overdosage, general symptomatic and supportive measures should be instituted promptly and maintained for as long as necessary. Treatment of overdosage would reasonably consist of emesis (ipecac syrup), except in patients with impaired consciousness, followed by the administration of activated charcoal to absorb any remaining drug. If vomiting is unsuccessful, or contraindicated, gastric lavage should be performed with normal saline. Saline cathartics may also be of value for rapid dilution of bowel contents. Loratadine is not eliminated by hemodialysis. It is not known if loratadine is eliminated by peritoneal dialysis.
|Cefamor Suspension is used to treat respiratory tract infections, inflammatory diseases of the middle ear (otitis media), skin and soft tissue infections, bone infections, infection of reproductive organs and the urinary system (genitourinary tract infections), worsening of long-term inflammation of the bronchi, and community-acquired pneumonia. It is a prescription medicine. This medicine works by killing the bacteria by blocking the bacterial cell-wall formation|
Bronchophane Syrup is used for Relief of runny nose, Sneezing, Itchy, Watery eyes, Itchy nose, Itchy throat due to hay fever or allergy, Relief of runny nose and sneezing due to common cold, Temporarily relief of cough caused by common cold, Flu, Or other conditions, Mild and chronic bronchial asthma, Low blood pressure, Cough, Congestion, Common cold, Bronchitis, Breathing illnesses and other conditions.Bronchophane Syrupmay also be used for purposes not listed in this medication guide.
Bronchophane Syrupcontains Dextromethorphan, Diphenhydramine, Ephedrine and Guaiphenesin as active ingredients.
Bronchophane Syrupworks by blocking the action of histamine; decreasing activity in the part of the brain that causes coughing; increasing cardiac output and inducing peripheral vasoconstriction; thinning the mucus in the air passages
|Ambrodil Drop is a medicine that helps treat wet cough (cough with mucus) associated with an acute sore throat, asthma, and chronic obstructive pulmonary disease (COPD) in children. It also relieves throat irritation, clears congestion, and enables easy breathing in your child.|
Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency.
|Content||Mosedin Syrup is used to relieve symptoms of seasonal allergy (seasonal allergic rhinitis) and other upper respiratory tract allergies. This medicine works by restricting the action of a natural chemical (called as, histamine) which acts on the body cell sites (H1 histamine receptor). Mosedin is also used to treat long-term hives.|
How to use
UseCefamor Suspensionas per the instructions provided by your doctor.
Cefamor is consumed with or without food. There is a slight reduction in absorption of Cefamor when given with food. Cefamor is usually taken every 6/12 hours for 7-14 days, depending on the disease being treated.
The typical dose of Cefamor for adults is 250 mg every 6 hours as a usual dose or 1000-4000 mg daily in divided doses for more severe infections. The usual dose for children is 25 mg/kg (11.4 mg/lb) - 50 mg/kg (22.7 mg/lb) in 3 equal doses and in severe infections, daily dose of 50 mg/kg (22.7 mg/lb) to 100 mg/kg (45.4 mg/lb) in uniformly divided doses. The maximum dose for adult patients of Cefamor is 4000 mg per day. This medicine is generally used for a period of 7-14 days for bacterial infections. Cefamor is commonly used at the same time every day.
Cefamor should be used as directed by the doctor even if you feel well, or even if you think that there is no need for you to use your medicine.
Talk to Your Doctor
Discuss with your doctor if your condition does not improve or worsens. Discuss with your doctor if watery or bloody stools, stomach cramps, and fever. If you have any kidney disease, the dose of the Cefamor should be reduced in kidney patients. If removing excess of water from the kidneys is required for kidney failure, the daily dose of Cefamor should not be more than 500mg.
Your doctor may prescribe a lower starting dose of this medicine to understand the impact on the body. Please follow your doctor's recommendations.
The effectiveness of this medicine may diminish when used for long periods of time.
Use in Children
If you are giving Cefamor Suspension to a child, be sure to use a product that is for use in children. Use the child's weight or age to find the right dose from the product package or medicine label. You can also read the dosage section of this page to know the correct dose for your child. Else, consult with your doctor and follow their recommendation.
Bronchophane Syrup is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:
The following is a list of possible side-effects that may occur from all constituting ingredients of Bronchophane Syrup. This is not a comprehensive list. These side-effects are possible, but do not always occur. Some of the side-effects may be rare but serious. Consult your doctor if you observe any of the following side-effects, especially if they do not go away.
Give Ambrodil Drop to your child by mouth with or without food along with a full glass of water. If your child develops an upset stomach, prefer giving it with food. You may require to give this medicine to your child for a few days to weeks, depending upon the severity of the disease. For maximum benefit, do not stop the medication abruptly by yourself even if your child starts to feel better and continue the medicine until the full prescribed course. Also, do not give more than the prescribed dose for fast relief as it may cause unwanted effects and worsen your child’s condition.Some of the common side effects of this medicine include excess salivation, altered taste, dry mouth and throat, oral numbness, fatigue, nausea, vomiting, diarrhea, stomach pain, indigestion, and skin rash. Usually, these episodes subside once your child’s body adapts to the medicine. However, if these effects persist or become bothersome for your child, report to your child’s doctor immediately.Narrate your child’s complete medical history, including any previous episode of respiratory illness, allergy, heart-problem, blood disorder, birth defects, airway obstruction, lung anomaly, sinus issues, liver impairment, and kidney malfunction. This information is critical for dose alterations and for planning your child’s overall treatment.
USES OF AMBRODIL DROP
BENEFITS OF AMBRODIL DROP
In Treatment of Cough with mucus
Ambrodil Drop helps gently soothe and relieve your child’s cough. It loosens thick mucus thereby making it easier to cough out. This makes breathing easy and reduces the frequency of coughing. Along with medications, drinking lukewarm water and gargling with warm salt water may also help ease symptoms for your child.
SIDE EFFECTS OF AMBRODIL DROP
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Ambrodil
HOW TO USE AMBRODIL DROP
Take this medicine in the dose and duration as advised by your doctor. Check the label for directions before use. Measure it with a marked dropper and take it as directed. Ambrodil Drop is to be taken with food.
HOW AMBRODIL DROP WORKS
Ambrodil Drop is a mucolytic medication. It thins and loosens mucus (phlegm) in the nose, windpipe, and lungs making it easier to cough out. Also, it relieves the pain and irritation due to sore and dry throat by rendering a soothing effect.
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Ambrodil Drop. Please consult your doctor.
CONSULT YOUR DOCTOR
Information regarding the use of Ambrodil Drop during pregnancy is not available. Please consult your doctor.
CONSULT YOUR DOCTOR
Information regarding the use of Ambrodil Drop during breastfeeding is not available. Please consult your doctor.
CONSULT YOUR DOCTOR
It is not known whether Ambrodil Drop alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Ambrodil Drop should be used with caution in patients with kidney disease. Dose adjustment of Ambrodil Drop may be needed. Please consult your doctor. The use of Ambrodil Drop is not recommended in children with severe kidney disease.
Ambrodil Drop should be used with caution in patients with liver disease. Dose adjustment of Ambrodil Drop may be needed.
Dosage & Administration
Average daily dose (preferably after meal):Pediatric Drops:
Ambroxol should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambroxol might not be expectorated.
Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported.
Pregnancy & Lactation
Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet.
Precautions & Warnings
Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
There are no reviews yet.